From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-09-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/4/5/e000548.full |